Psychedelic science in post-COVID-19 psychiatry
Kelly, J. R., Crockett, M. T., Alexander, L., Haran, M., Baker, A., Burke, L., & O’Keane, V. | Irish journal of psychological medicine | 19 Aug 2020
Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies
Breeksema, J. J., Niemeijer, A. R., Krediet, E., Vermetten, E., & Schoevers, R. A | CNS drugs | 17 August 2020
The rise, fall, and possible rise of LSD
Snelders, S., & Pieters, T. | Tijdschrift Voor Psychiatrie | August 2020
[Psychedelics in the treatment of substance use disorders and psychosis]
van den Brink, W., Breeksema, J. J., Vermetten, E., & Schoevers, R. A. | Tijdschrift Voor Psychiatrie | 1 August 2020
Psilocybin and LSD Have No Long-Lasting Effects in an Animal Model of Alcohol Relapse
Meinhardt, M. W., Güngör, C., Skorodumov, I., Mertens, L. J., & Spanagel, R. | Neuropsychopharmacology | 5 May 2020
Psychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I. | American Journal of Psychiatry | 1 May 2020
A Single Administration of the Atypical Psychedelic Ibogaine or Its Metabolite Noribogaine Induces an Antidepressant-Like Effect in Rats
Rodríguez, P., Urbanavicius, J., Prieto, J. P., Fabius, S., Reyes, A. L., Havel, V., ... & Carrera, I. | ACS Chemical Neuroscience | 24 April 2020
Psilocybin Therapeutic Research: The Present and Future Paradigm
Kargbo, R. B. | ACS Medicinal Chemistry Letters | 2 March 2020
A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses
Chi, T., & Gold, J. A. | Journal of the Neurological Sciences | 30 January 2020
Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey.
Garcia-Romeu, A., Davis, A. K., Erowid, E., Griffiths, R. R., & Johnson, M. W. | Frontiers in psychiatry | 22 January 2020
Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials.
Fuentes, J. J., Fonseca, F., Elices, M., Farre, M., & Torrens, M. | Frontiers in Psychiatry | 21 January 2020
Preliminary Report on the Effects of a Low Dose of LSD on Resting-State Amygdala Functional Connectivity.
Bershad, A. K., Preller, K. H., Lee, R., Keedy, S., Wren-Jarvis, J., Bremmer, M. P., & de Wit, H. | Biological Psychiatry: Cognitive Neuroscience and Neuroimaging | 20 December 2019
Neurotrophic mechanisms of psychedelic therapy
Corne, R., & Mongeau, R. | Biologie aujourd'hui | 12 December 2019
4-MeO-PCP and 3-MeO-PCMo, new dissociative drugs, produce rewarding and reinforcing effects through activation of mesolimbic dopamine pathway and alteration of accumbal CREB, deltaFosB, and BDNF levels
Abiero, A., Botanas, C. J., Custodio, R. J., Sayson, L. V., Kim, M., Lee, H. J. & Cheong, J. H. | Psychopharmacology | 11 December 2019
Therapeutic use of serotoninergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms.
dos Santos, R. G., & Hallak, J. E. C. | Neuroscience & Biobehavioral Reviews | 3 December 2019
Searching for Treatments for Cocaine Use Disorder: The Quest Continues.
Brady, K. T. | American Journal of Psychiatry | 1 November 2019
Exploring ayahuasca‐assisted therapy for addiction: A qualitative analysis of preliminary findings among an Indigenous community in Canada
Argento, E., Capler, R., Thomas, G., Lucas, P., & Tupper, K. W. | Drug and alcohol review | 5 September 2019
Effects of the synthetic psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) on ethanol consumption and place conditioning in male mice.
Oppong-Damoah, A., Curry, K. E., Blough, B. E., Rice, K. C., & Murnane, K. S. | Psychopharmacology | 15 July 2019
First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants
Sessa, B., Sakal, C., O’Brien, S., & Nutt, D. | BMJ Case Reports CP | 15 July 2019
Psychedelic drugs-a new era in psychiatry?
Nutt, D. | Dialogues in clinical neuroscience | June 2019
Dimethyltryptamine: Endogenous Role and Therapeutic Potential.
Rodrigues, A. V., Almeida, F. J., & Vieira-Coelho, M. A. | Journal of psychoactive drugs | 25 April 2019
Serotonin transporter-ibogaine complexes illuminate mechanisms of inhibition and transport
Coleman, J. A., Yang, D., Zhao, Z., Wen, P. C., Yoshioka, C., Tajkhorshid, E., & Gouaux, E. | Nature | 24 April 2019
Ibogaine and Subjective Experience: Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder
Brown, T. K., Noller, G. E., & Denenberg, J. O. | Journal of psychoactive drugs | 9 April 2019
A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy.
Sessa, B., Higbed, L., & Nutt, D. | Frontiers in Psychiatry | 20 March 2019
Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits.
Marton, S., González, B., Rodríguez, S., Miquel, E., Martínez-Palma, L., Pazos, M., ... & Scorza, C. | Frontiers in pharmacology | 5 March 2019